NASDAQ:PTGX Protagonist Therapeutics (PTGX) Stock Price, News & Analysis $140.56 +1.37 (+0.99%) As of 12:07 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Protagonist Therapeutics Stock (NASDAQ:PTGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PTGX alerts:Sign Up Key Stats Today's Range$138.72▼$141.7150-Day Range$132.28▼$158.6252-Week Range$62.24▼$160.81Volume202,222 shsAverage Volume710,716 shsMarket Capitalization$9.10 billionP/E Ratio136.31Dividend YieldN/APrice Target$147.13Consensus RatingModerate Buy Company Overview Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company focused on developing peptide-based medicines for chronic immune-mediated and hematologic diseases. The company uses its proprietary technology platform to design peptides intended to selectively interact with disease-relevant biological targets. Protagonist’s pipeline includes icotrokinra, formerly known as JNJ-2113, an investigational oral peptide that selectively targets the interleukin-23 receptor. The program is being developed through a collaboration with Johnson & Johnson for conditions including psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. The company is also developing rusfertide, formerly known as PTG-300, an investigational hepcidin mimetic designed to regulate iron availability and treat polycythemia vera and other myeloproliferative neoplasms. Rusfertide is being advanced through a collaboration with Takeda. Founded in 2006, Protagonist is headquartered in Newark, New Jersey, and conducts research and clinical development activities through collaborations and partnerships serving international markets. The company is led by Dinesh V. Patel, who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Protagonist Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScorePTGX MarketRank™: Protagonist Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 747th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingModerate Buy Consensus RatingProtagonist Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on no strong buy ratings, 16 buy ratings, 2 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Protagonist Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageProtagonist Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Protagonist Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Protagonist Therapeutics are expected to decrease in the coming year, from $4.22 to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is 135.97, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is 135.97, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.64.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 14.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Protagonist Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.27% of the float of Protagonist Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 15.13, which indicates bearish sentiment.Change versus previous monthShort interest in Protagonist Therapeutics has recently increased by 5.54%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.83 News SentimentProtagonist Therapeutics has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Protagonist Therapeutics this week, compared to 4 articles on an average week.MarketBeat Follows6 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,131,367.00 in company stock.Percentage Held by Insiders5.19% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Protagonist Therapeutics' insider trading history. Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTGX Stock News HeadlinesProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Rated "Moderate Buy" by Wall Street BrokeragesOctober 2 at 2:15 AM | americanbankingnews.comInsider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 7,278 SharesSeptember 11, 2026 | insidertrades.comThe SEC Just Opened The Floodgates…The SEC removed the 25 year old Pattern Day Trader rule in June 2026, cutting the minimum to open a trading account to just 2,000 dollars. Small cap stocks like ONFO, CURR, RMSG, TMDE and VSME have already posted gains ranging from 140 percent to 482 percent, some in a single day. Tim Bohen, known for flagging Tesla at 37 and Nvidia at 6.93, believes this shift could trigger the next major small cap breakout.October 2 at 1:00 AM | StocksToTrade (Ad)Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 9, 2026 | seekingalpha.comProtagonist Therapeutics authorizes $300M share repurchase programSeptember 8, 2026 | msn.comMIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?September 4, 2026 | finance.yahoo.comAnalysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)September 2, 2026 | theglobeandmail.comAnalysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Protagonist Therapeutics (PTGX)September 2, 2026 | theglobeandmail.comSee More Headlines PTGX Stock Analysis - Frequently Asked Questions How have PTGX shares performed this year? Protagonist Therapeutics' stock was trading at $87.34 at the start of the year. Since then, PTGX stock has increased by 59.7% and is now trading at $139.5250. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) released its quarterly earnings results on Wednesday, August, 5th. The company reported $2.29 EPS for the quarter, topping analysts' consensus estimates of $2.27 by $0.02. The business's revenue was up 3746.8% on a year-over-year basis. When did Protagonist Therapeutics IPO? Protagonist Therapeutics (PTGX) raised $90 million in an initial public offering on Wednesday, August 10th 2016. The company issued 7,500,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protagonist Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AUO (AUOTY). Company Calendar Last Earnings8/05/2026Today10/02/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PTGX's financial health is in the Green zone, according to TradeSmith. PTGX has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PTGX CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees141Year Founded2006Price Target and Rating Average Price Target for Protagonist Therapeutics$147.13 High Price Target$190.00 Low Price Target$82.00 Potential Upside/Downside+4.9%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)$1.03 Trailing P/E Ratio136.21 Forward P/E Ratio33.25 P/E GrowthN/ANet Income-$130.15 million Net Margins29.40% Pretax Margin29.91% Return on Equity12.03% Return on Assets11.23% Debt Debt-to-Equity RatioN/A Current Ratio21.71 Quick Ratio21.71 Sales & Book Value Annual Sales$46.02 million Price / Sales197.28 Cash FlowN/A Price / Cash FlowN/A Book Value$9.83 per share Price / Book14.27Miscellaneous Outstanding Shares64,710,000Free Float61,350,000Market Cap$9.08 billion OptionableOptionable Beta1.53 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PTGX) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredThis AI fund posted a 34 percent annualized payout last monthOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredThe rich already moved their moneyBy the time a crash hits the news, it's already too late to protect your money. Parkview Capital's free Mar...Parkview Capital Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...Crypto 101 Media | SponsoredThe SEC Just Opened The Floodgates…The SEC removed the 25 year old Pattern Day Trader rule in June 2026, cutting the minimum to open a trading ac...StocksToTrade | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
